Cargando…

PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response

In recent years, phosphodiesterase (PDE) inhibitors have been frequently tested for the treatment of experimental inflammatory and immune disorders. It is suggested that anti-inflammatory properties of PDE inhibitors are related to their ability to increase cAMP levels. The aim of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Świerczek, Artur, Wyska, Elżbieta, Baś, Sebastian, Woyciechowska, Marta, Mlynarski, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599463/ https://www.ncbi.nlm.nih.gov/pubmed/28730281 http://dx.doi.org/10.1007/s00210-017-1406-z

Ejemplares similares

Comparative Assessment of the New PDE7 Inhibitor – GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach
por: Świerczek, Artur, et al.
Publicado: (2020)

PK/PD Modeling of the PDE7 Inhibitor—GRMS-55 in a Mouse Model of Autoimmune Hepatitis
por: Świerczek, Artur, et al.
Publicado: (2021)

A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling
por: Wójcik-Pszczoła, Katarzyna, et al.
Publicado: (2020)

PDE4-Mediated cAMP Signalling
por: Fertig, Bracy A., et al.
Publicado: (2018)

Evaluation of analgesic and anti-inflammatory activity of purine-2,6-dione-based TRPA1 antagonists with PDE4/7 inhibitory activity
por: Zygmunt, Małgorzata, et al.
Publicado: (2022)

Anti‐inflammatory effects of dexamethasone in COVID‐19 patients: Translational population PK/PD modeling and simulation
por: Świerczek, Artur, et al.
Publicado: (2023)

Imaging of PDE2- and PDE3-Mediated cGMP-to-cAMP Cross-Talk in Cardiomyocytes
por: Pavlaki, Nikoleta, et al.
Publicado: (2018)

Cigarette smoke up‐regulates PDE3 and PDE4 to decrease cAMP in airway cells
por: Zuo, Haoxiao, et al.
Publicado: (2018)

cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features
por: Nourian, Yazdan Hasani, et al.
Publicado: (2023)

Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro
por: Schmetterer, Klaus G., et al.
Publicado: (2019)

Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation
por: Dolce, Bernardo, et al.
Publicado: (2020)

Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice
por: Wyska, Elżbieta, et al.
Publicado: (2015)

PDE4 and Epac1 Synergistically Promote Rectal Carcinoma via the cAMP Pathway
por: Kong, Xiangyu, et al.
Publicado: (2019)

Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases
por: Sadek, Mirna S., et al.
Publicado: (2020)

Pharmacophore Modeling and Virtual Screening for the Discovery of New type 4 cAMP Phosphodiesterase (PDE4) Inhibitors
por: Niu, Miaomiao, et al.
Publicado: (2013)

The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP/AMPK/SIRT1 pathway
por: Dong, Xiao-Liu, et al.
Publicado: (2021)

Treatment of Cardiovascular Dysfunction With PDE5-Inhibitors – Temperature Dependent Effects on Transport and Metabolism of cAMP and cGMP
por: Selli, Anders L., et al.
Publicado: (2021)

The NO/cGMP pathway inhibits transient cAMP signals through the activation of PDE2 in striatal neurons
por: Polito, Marina, et al.
Publicado: (2013)

Modulation of cGMP/cAMP crosstalk on the level of PDE3 in animals lacking NO-sensitive guanylyl cyclase
por: Friebe, Andreas, et al.
Publicado: (2015)

Enhancement of cAMP-mediated inotropic responses by CNP is regulated differently by PDE2 in normal and failing hearts
por: Meier, Silja, et al.
Publicado: (2015)

Dominant-Negative Attenuation of cAMP-Selective Phosphodiesterase PDE4D Action Affects Learning and Behavior
por: Bolger, Graeme B., et al.
Publicado: (2020)

The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches
por: Lugnier, Claire
Publicado: (2022)

Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)
por: Cameron, Ryan T., et al.
Publicado: (2013)

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
por: Perez-Aso, Miguel, et al.
Publicado: (2015)

Editorial: Frontiers in the Pharmacological Manipulation of Intracellular cAMP Levels
por: Baillie, George S., et al.
Publicado: (2016)

Efficacy of the Multi-Target Compound E153 in Relieving Pain and Pruritus of Different Origins
por: Mogilski, Szczepan, et al.
Publicado: (2023)

PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome
por: Terrin, Anna, et al.
Publicado: (2012)

Pyruvate Upregulates Hepatic FGF21 Expression by Activating PDE and Inhibiting cAMP–Epac–CREB Signaling Pathway
por: Zhao, Yan-Yan, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Evaluation of a New Purine-2,6-Dione Derivative in Rodents with Experimental Autoimmune Diseases
por: Świerczek, Artur, et al.
Publicado: (2022)

Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway
por: Khalifa, Mona, et al.
Publicado: (2022)

Studying GPCR/cAMP pharmacology from the perspective of cellular structure
por: Wright, Peter T., et al.
Publicado: (2015)

PdeH, a High-Affinity cAMP Phosphodiesterase, Is a Key Regulator of Asexual and Pathogenic Differentiation in Magnaporthe oryzae
por: Ramanujam, Ravikrishna, et al.
Publicado: (2010)

β(2)-Agonist Induced cAMP Is Decreased in Asthmatic Airway Smooth Muscle Due to Increased PDE4D
por: Trian, Thomas, et al.
Publicado: (2011)

DISC1–ATF4 transcriptional repression complex: dual regulation of the cAMP-PDE4 cascade by DISC1
por: Soda, T, et al.
Publicado: (2013)

Inhibition of PDE10A-Rescued TBI-Induced Neuroinflammation and Apoptosis through the cAMP/PKA/NLRP3 Pathway
por: Huang, Jin, et al.
Publicado: (2022)

CRISPR/Cas9 Knock-Out in Primary Neonatal and Adult Cardiomyocytes Reveals Distinct cAMP Dynamics Regulation by Various PDE2A and PDE3A Isoforms
por: Skryabin, Egor B., et al.
Publicado: (2023)

Correction to: Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway
por: Khalifa, Mona, et al.
Publicado: (2022)

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells
por: Henderson, D J P, et al.
Publicado: (2014)

CNP-pGC-cGMP-PDE3-cAMP Signal Pathway Upregulated in Gastric Smooth Muscle of Diabetic Rats
por: Cai, Ying-Lan, et al.
Publicado: (2015)

PDE2A2 regulates mitochondria morphology and apoptotic cell death via local modulation of cAMP/PKA signalling
por: Monterisi, Stefania, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rsbpen134j3oi63t7pbb5nsfb7